Subscribe
designer491-3
designer491 / iStockphoto.com
3 December 2018Americas

GSK seeks to boost oncology repertoire with $5.1bn acquisition

GSK has agreed to buy US oncology company Tesaro for $5.1 billion (£4 billion), in a move designed to strengthen its anti-cancer offering.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
GSK completes buyout of Novartis from joint venture
7 June 2018   GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.
Americas
GSK and Merck KGaA unite in €3.7bn immunotherapy deal
6 February 2019   UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.
Big Pharma
Vaccines growth offsets Advair generic pain for GSK
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
GSK completes buyout of Novartis from joint venture
7 June 2018   GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.
Americas
GSK and Merck KGaA unite in €3.7bn immunotherapy deal
6 February 2019   UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.
Big Pharma
Vaccines growth offsets Advair generic pain for GSK
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.

More on this story

Big Pharma
GSK completes buyout of Novartis from joint venture
7 June 2018   GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.
Americas
GSK and Merck KGaA unite in €3.7bn immunotherapy deal
6 February 2019   UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.
Big Pharma
Vaccines growth offsets Advair generic pain for GSK
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers